Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

Key Takeaways The VOR stock surged after licensing ex-China rights to telitacicept from RemeGen. The licensing deal totals $125M upfront and stock, plus more than $4B in potential milestones and royalties. VOR appoints Jean-Paul Kress as its new chief executive officer and chairman of the board.Shares of Vor Bio (VOR) have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based pharmaceutical co ...